BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, February 13, 2026
Breaking News: BioWorld Science 2025 Year in Review
See today's BioWorld Science
Home
» FDA clears allogenic cellular therapy Allostem to enter clinic for type 1 diabetes
To read the full story,
subscribe
or
sign in
.
Endocrine/Metabolic
FDA clears allogenic cellular therapy Allostem to enter clinic for type 1 diabetes
Nov. 4, 2022
Creative Medical Technology Holdings Inc. has received FDA clearance of its IND application for a clinical trial of Allostem in type 1 diabetes.
BioWorld Science
Cell therapy
Endocrine/metabolic
Cell therapy
FDA
IND
